Company Profile

PLx Pharma Inc., (NASDAQ:PLXP) is a late-stage specialty pharmaceutical company organized around developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin using the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing anti-platelet effectiveness for cardiovascular disease prevention. The firm's product pipeline also includes other oral NSAIDs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation. In December 2016, publicly traded Dipexium Pharmaceuticals Inc. and closely held PLx Pharma Inc. merged in a stock swap in which PLx shareholders received newly issued Dipexium common shares. PLx had earlier filed for its own IPO on the Nasdaq but later in 2016 withdrew. Effective as of April 2017, the combined company—which changed its name to PLx Pharma Inc. immediately following the merger—began trading on the NASDAQ Capital Market under the symbol “PLXP”